News & Updates
Filter by Specialty:
Long COVID symptoms may persist 3 years post-infection
One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.
Long COVID symptoms may persist 3 years post-infection
01 Oct 2025
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
Results from the phase III HARMONi trial presented at WCLC 2025 show that adding ivonescimab to chemotherapy prolongs progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).
Add-on ivonescimab nearly halves risk of progression, death in EGFR+ NSCLC
30 Sep 2025
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
